IMPACT-OC Interpretable Multimodal Predictive Agents and Digital Twins for Ovarian Cancer
- Coordinator
- Danube Private University GmbH, Austria
- Runs
- 1 October 2026 to 30 September 2030
- Status
- Running
- EU funding
- €4.0m
- Total cost
- —
- Partners
- 10 organisations in 5 countries
- Type
- European Innovation Council
- Grant agreement
- 101306266
What the project is doing
In the project's own words, from its summary on CORDIS.
IMPACT-OC builds an interpretable, standards-first decision-support stack not only for patients with ovarian cancer but also for indeterminate adnexal lesions and women with unknown hereditary risk for developing ovarian cancer. Calibrated modality-specific agents (imaging, pathology, genomics, clinical text) and a super-agent fuse evidence with guideline logic, site policies and explicit uncertainty to produce auditable recommendations.
A longitudinal digital twin forecasts trajectories and short what-if scenarios. Outputs surface via a clinician dashboard and report agent. Privacy-preserving scale-up is central: data stay on site; federated learning exchanges encrypted updates; safety-gated synthetic datasets support benchmarking and stress tests. All assets interoperate through DICOM/DICOMweb for imaging and HL7 FHIR/OMOP for structured data, with DCAT-AP metadata, provenance and model cards.
Multilingual NLP and adapted foundation models are packaged as lightweight services. Validation is strictly non-interventional (TRL-4), using retrospective and time-shifted feeds for internal–external testing, calibration, uncertainty quality and fairness audits across centres, scanners, languages and subgroups—without influencing care. Three pilots anchor evaluation: expertise-aware triage between primary surgery and neoadjuvant chemotherapy in advanced HGSOC; ultrasound-based preselection for HRD/BRCA testing; and calibrated multimodal risk for adnexal-mass management.
Data access from four European centres enables a three-period plan: foundations (ethics, harmonisation, baseline agents), integration (digital twin v1, dashboards, shadow-mode replay) and final validation (explainability, robustness, fairness). Outputs—open interfaces, interoperability profiles and CE-readiness materials—support adoption by hospitals and SMEs, aligned with the EU AI Act, Medical Device Regulation, EUCAIM and EHDS.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Danube Private University GmbH | Krems-Stein | Austria | Coordinator |
| Duervation GmbH | Krems an der Donau | Austria | Participant |
| Ecoplus.niederosterreichs Wirtschaftsagentur GmbH | St Polten | Austria | Associatedpartner |
| Karlsruher Institut Fuer Technologie | Karlsruhe | Germany | Participant |
| Nec Laboratories Europe GmbH | Heidelberg | Germany | Participant |
| Ruprecht-Karls-Universitaet Heidelberg | Heidelberg | Germany | Participant |
| Institut Regional Du Cancer De Montpellier | Montpellier Cedex 5 | France | Participant |
| Fondazione Policlinico Universitario Agostino Gemelli Irccs | Roma | Italy | Participant |
| Politecnico Di Milano | Milano | Italy | Participant |
| The Chancellor Masters and Scholars of the University of Cambridge | Cambridge | United Kingdom | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI